SPL starpharma holdings limited

Bye Bye Mundipharma, page-8

  1. 2,411 Posts.
    lightbulb Created with Sketch. 629
    Here is the original announcement from 27 June 2018!

    https://starpharma.com/news/story/starpharma-licenses-vivagel-bv-to-mundipharma-for-europe

    It clearly states up front fees of up to $20.9M. How much of that have we seen?

    It also states:

    Consistent with the previous Mundipharma deal, Starpharma will receive returns via a revenue share on VivaGel® BV sales and is also eligible to receive signing, launch and other commercial milestones. Under the European deal, eligible milestones total up to A$20.9 million (US$15.5 million), including a A$2.0 million (US$1.5 million) upfront payment. The combination of territories now under licence with Mundipharma means Starpharma is eligible to receive total signing, regulatory and commercial milestones of up to A$33.3 million (US$24.7 million), in addition to receiving revenue share.

    The term of this licence is 15 years and contains commercial performance obligations, including minimum annual purchases by Mundipharma. Mundipharma is responsible for marketing, promotion and sales of the product in its licensed territories. Starpharma retains ownership of the VivaGel® BV trademark and will supply Mundipharma with VivaGel® BV. Other commercial terms of the agreement remain confidential.
    Last edited by joohnno: 07/02/22
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
10.0¢
Change
0.006(6.38%)
Mkt cap ! $41.82M
Open High Low Value Volume
9.6¢ 10.0¢ 9.5¢ $64.33K 653.1K

Buyers (Bids)

No. Vol. Price($)
1 20000 9.9¢
 

Sellers (Offers)

Price($) Vol. No.
10.5¢ 226100 5
View Market Depth
Last trade - 16.10pm 10/07/2025 (20 minute delay) ?
SPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.